Resverlogix Corp. Logo

Resverlogix Corp.

RVXCF

(1.5)
Stock Price

0,05 USD

-171.26% ROA

14.46% ROE

-1.47x PER

Market Cap.

13.799.070,00 USD

-9.47% DER

0% Yield

0% NPM

Resverlogix Corp. Stock Analysis

Resverlogix Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Resverlogix Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-0.18x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (-11%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

The stock's ROE falls within an average range (1.46%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

5 ROA

The stock's ROA (-14.81%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Resverlogix Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Resverlogix Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Resverlogix Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Resverlogix Corp. Revenue
Year Revenue Growth
2001 5.902
2003 0 0%
2004 17.591 100%
2005 175.057 89.95%
2006 243.638 28.15%
2007 289.951 15.97%
2008 0 0%
2009 138.166 100%
2010 2.804 -4829.22%
2011 82.876 96.62%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Resverlogix Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2003 194.133 100%
2004 263.923 26.44%
2005 1.249.975 78.89%
2006 3.031.451 58.77%
2007 9.568.290 68.32%
2008 14.599.400 34.46%
2009 11.404.839 -28.01%
2010 15.105.442 24.5%
2011 14.415.506 -4.79%
2012 19.738.000 26.97%
2013 -28.430.000 169.43%
2014 -9.809.000 -189.84%
2015 -4.185.000 -134.38%
2016 15.681.000 126.69%
2017 29.875.000 47.51%
2018 37.786.000 20.94%
2019 32.230.000 -17.24%
2020 15.801.000 -103.97%
2021 4.515.000 -249.97%
2022 5.507.000 18.01%
2023 1.908.000 -188.63%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Resverlogix Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 7.515.870 100%
2012 0 0%
2013 -6.207.000 100%
2014 -4.228.000 -46.81%
2015 -4.273.000 1.05%
2016 4.326.000 198.77%
2017 4.269.000 -1.34%
2018 4.070.000 -4.89%
2019 6.510.000 37.48%
2020 6.776.000 3.93%
2021 11.120.000 39.06%
2022 6.941.000 -60.21%
2023 2.232.000 -210.98%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Resverlogix Corp. EBITDA
Year EBITDA Growth
2001 -39.179
2003 -490.208 92.01%
2004 -1.284.292 61.83%
2005 -2.755.999 53.4%
2006 -6.137.051 55.09%
2007 -15.366.069 60.06%
2008 -24.358.541 36.92%
2009 -18.945.193 -28.57%
2010 -21.838.520 13.25%
2011 -21.818.464 -0.09%
2012 -24.181.000 9.77%
2013 26.253.000 192.11%
2014 73.408.000 64.24%
2015 3.538.000 -1974.84%
2016 -26.215.000 113.5%
2017 -28.818.000 9.03%
2018 -30.542.000 5.64%
2019 85.996.000 135.52%
2020 -74.152.000 215.97%
2021 -14.867.000 -398.77%
2022 -11.742.000 -26.61%
2023 -3.644.000 -222.23%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Resverlogix Corp. Gross Profit
Year Gross Profit Growth
2001 5.902
2003 0 0%
2004 17.591 100%
2005 175.057 89.95%
2006 243.638 28.15%
2007 289.951 15.97%
2008 0 0%
2009 138.166 100%
2010 2.804 -4829.22%
2011 82.876 96.62%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Resverlogix Corp. Net Profit
Year Net Profit Growth
2001 -39.179
2003 -512.827 92.36%
2004 -1.410.837 63.65%
2005 -2.837.311 50.28%
2006 -6.383.605 55.55%
2007 -16.547.803 61.42%
2008 -28.126.436 41.17%
2009 -18.102.305 -55.37%
2010 -27.465.764 34.09%
2011 -22.121.042 -24.16%
2012 -18.782.000 -17.78%
2013 43.355.000 143.32%
2014 -55.104.000 178.68%
2015 18.323.000 400.74%
2016 -19.715.000 192.94%
2017 -46.210.000 57.34%
2018 -58.310.000 20.75%
2019 -162.798.000 64.18%
2020 118.025.000 237.94%
2021 -24.771.000 576.46%
2022 -3.610.000 -586.18%
2023 -17.792.000 79.71%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Resverlogix Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 -1 0%
2008 -1 100%
2009 -1 0%
2010 -1 0%
2011 0 0%
2012 0 0%
2013 1 0%
2014 -1 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -1 0%
2020 1 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Resverlogix Corp. Free Cashflow
Year Free Cashflow Growth
2001 -10.978
2003 -891.783 98.77%
2004 -979.506 8.96%
2005 -2.325.400 57.88%
2006 -4.995.993 53.45%
2007 -10.746.479 53.51%
2008 -20.183.298 46.76%
2009 -13.214.140 -52.74%
2010 -18.687.896 29.29%
2011 -19.641.033 4.85%
2012 -24.593.000 20.14%
2013 -29.541.000 16.75%
2014 -13.972.000 -111.43%
2015 -10.308.000 -35.55%
2016 -22.210.000 53.59%
2017 -23.228.000 4.38%
2018 -25.670.000 9.51%
2019 -49.456.000 48.1%
2019 -49.456.000 0%
2020 -17.843.000 -177.17%
2021 -8.901.000 -100.46%
2022 -3.991.000 -123.03%
2023 57.000 7101.75%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Resverlogix Corp. Operating Cashflow
Year Operating Cashflow Growth
2001 -10.978
2003 -453.563 97.58%
2004 -885.041 48.75%
2005 -2.179.700 59.4%
2006 -4.410.462 50.58%
2007 -9.925.924 55.57%
2008 -19.646.326 49.48%
2009 -13.010.388 -51%
2010 -18.337.377 29.05%
2011 -19.238.914 4.69%
2012 -24.028.000 19.93%
2013 -28.996.000 17.13%
2014 -13.201.000 -119.65%
2015 -8.499.000 -55.32%
2016 -21.422.000 60.33%
2017 -22.669.000 5.5%
2018 -25.133.000 9.8%
2019 -48.834.000 48.53%
2019 -48.834.000 0%
2020 -17.343.000 -181.58%
2021 -8.024.000 -116.14%
2022 -3.541.000 -126.6%
2023 180.000 2067.22%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Resverlogix Corp. Capital Expenditure
Year Capital Expenditure Growth
2001 0
2003 438.221 100%
2004 94.465 -363.9%
2005 145.699 35.16%
2006 585.531 75.12%
2007 820.555 28.64%
2008 536.972 -52.81%
2009 203.752 -163.54%
2010 350.518 41.87%
2011 402.118 12.83%
2012 565.000 28.83%
2013 545.000 -3.67%
2014 771.000 29.31%
2015 1.809.000 57.38%
2016 788.000 -129.57%
2017 559.000 -40.97%
2018 537.000 -4.1%
2019 622.000 13.67%
2019 622.000 0%
2020 500.000 -24.4%
2021 877.000 42.99%
2022 450.000 -94.89%
2023 123.000 -265.85%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Resverlogix Corp. Equity
Year Equity Growth
2001 259.643
2003 942.208 72.44%
2004 2.596.962 63.72%
2005 9.844.291 73.62%
2006 7.481.093 -31.59%
2007 -1.020.782 832.88%
2008 5.440.832 118.76%
2009 11.608.050 53.13%
2010 4.463.422 -160.07%
2011 4.299.726 -3.81%
2012 2.741.000 -56.87%
2013 -29.504.000 109.29%
2014 -63.215.000 53.33%
2015 -73.727.000 14.26%
2016 -56.429.000 -30.65%
2017 -101.569.000 44.44%
2018 -83.677.000 -21.38%
2019 -207.722.000 59.72%
2019 -207.722.000 0%
2020 -64.112.000 -224%
2021 -59.870.000 -7.09%
2022 -59.281.000 -0.99%
2023 -71.531.000 17.13%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Resverlogix Corp. Assets
Year Assets Growth
2001 295.290
2003 1.082.059 72.71%
2004 2.694.560 59.84%
2005 10.197.657 73.58%
2006 8.060.451 -26.51%
2007 14.996.715 46.25%
2008 20.709.314 27.58%
2009 18.905.474 -9.54%
2010 8.433.031 -124.18%
2011 8.426.686 -0.08%
2012 12.371.000 31.88%
2013 20.496.000 39.64%
2014 3.026.000 -577.33%
2015 21.156.000 85.7%
2016 40.097.000 47.24%
2017 10.867.000 -268.98%
2018 8.278.000 -31.28%
2019 16.287.000 49.17%
2019 16.287.000 0%
2020 11.378.000 -43.14%
2021 9.982.000 -13.99%
2022 8.115.000 -23.01%
2023 7.826.000 -3.69%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Resverlogix Corp. Liabilities
Year Liabilities Growth
2001 35.647
2003 139.851 74.51%
2004 97.598 -43.29%
2005 353.365 72.38%
2006 579.358 39.01%
2007 16.017.497 96.38%
2008 15.268.482 -4.91%
2009 7.297.423 -109.23%
2010 3.969.609 -83.83%
2011 4.126.960 3.81%
2012 9.630.000 57.14%
2013 50.000.000 80.74%
2014 66.241.000 24.52%
2015 94.883.000 30.19%
2016 96.526.000 1.7%
2017 112.436.000 14.15%
2018 91.955.000 -22.27%
2019 224.009.000 58.95%
2019 224.009.000 0%
2020 75.490.000 -196.74%
2021 69.852.000 -8.07%
2022 67.396.000 -3.64%
2023 79.357.000 15.07%

Resverlogix Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.03
Price to Earning Ratio
-1.47x
Price To Sales Ratio
0x
POCF Ratio
-13.01
PFCF Ratio
-10.14
Price to Book Ratio
-0.19
EV to Sales
0
EV Over EBITDA
-3.1
EV to Operating CashFlow
-19.35
EV to FreeCashFlow
-15.04
Earnings Yield
-0.68
FreeCashFlow Yield
-0.1
Market Cap
0,01 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.45
Graham NetNet
-0.29

Income Statement Metrics

Net Income per Share
-0.03
Income Quality
0.2
ROE
0.14
Return On Assets
-1.19
Return On Capital Employed
0.4
Net Income per EBT
1
EBT Per Ebit
1.28
Ebit per Revenue
0
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0.29
Capex to Revenue
0
Capex to Depreciation
-0.49
Return on Invested Capital
0.11
Return on Tangible Assets
-1.71
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,26
Tangible Book Value per Share
-0.26
Shareholders Equity per Share
-0.26
Interest Debt per Share
0.03
Debt to Equity
-0.09
Debt to Assets
0.87
Net Debt to EBITDA
-1.01
Current Ratio
0.11
Tangible Asset Value
-0,07 Bil.
Net Current Asset Value
-0,08 Bil.
Invested Capital
-0.09
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0.3
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
2371000
Debt to Market Cap
0.49

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Resverlogix Corp. Dividends
Year Dividends Growth

Resverlogix Corp. Profile

About Resverlogix Corp.

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

CEO
Mr. Donald J. McCaffrey
Employee
19
Address
4820 Richard Road SW
Calgary, T3E 6L1

Resverlogix Corp. Executives & BODs

Resverlogix Corp. Executives & BODs
# Name Age
1 Mr. Donald J. McCaffrey
Co-Founder, Chairman, President, Chief Executive Officer & Secretary
70
2 Sarah Zapotichny
Director of Investor Relations & Corporate Communications
70
3 Mr. Aaron Bradley Cann C.A., CPA, CBV
Chief Financial Officer
70
4 Dr. Michael Sweeney M.D.
Senior Vice President of Clinical Development
70
5 Dr. Ewelina Kulikowski Ph.D.
Chief Scientific Officer
70

Resverlogix Corp. Competitors